Tuesday, October 21, 2014 1:53:31 PM
Fenig
The new target is as close to exposure as possible rather than waiting 21 days.
The sooner the better.
It would be nice to know how long after exposure TKMR was added into the affected patients.
Echo21
The new target is as close to exposure as possible rather than waiting 21 days.
The sooner the better.
It would be nice to know how long after exposure TKMR was added into the affected patients.
Echo21
Recent ABUS News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/27/2026 08:01:33 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 09:29:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 11:31:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 11:31:16 AM
- Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/13/2026 11:30:00 AM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/28/2026 09:54:41 PM
- Arbutus Shares Jump After FDA Grants Fast Track Status to Hepatitis B Therapy • IH Market News • 04/15/2026 02:09:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 11:31:20 AM
- Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B • GlobeNewswire Inc. • 04/15/2026 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/14/2026 09:05:20 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/14/2026 09:02:17 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/13/2026 11:56:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:31:10 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/23/2026 11:30:44 AM
- Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute • IH Market News • 03/04/2026 11:24:49 AM
- Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna • GlobeNewswire Inc. • 03/03/2026 09:15:00 PM
- Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna • GlobeNewswire Inc. • 03/03/2026 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 09:01:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2026 09:01:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 01:21:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 01:21:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2026 12:41:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2025 01:00:44 PM
